Gilead, GSK, share potential advancements in HIV
Two significant HIV announcements have already dropped at the Conference on Retroviruses and Opportunistic Infections in Seattle this week, courtesy of Gilead, GSK's ViiV Healthcare and J&J's Janssen Sciences Ireland.